The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report
The American Journal on Addictions · 2024
DOI: 10.1111/ajad.13516 ↗Kurz gefasst
Fallbericht in der Zeitschrift The American Journal on Addictions, 2024. Verfasst von Amber N Edinoff und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts, USA. Hauptthemen laut MEDLINE: Alcoholism, Substance Withdrawal Syndrome, Glycerophospholipids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.
Abstract (Originalsprache)
Background and Objectives The decision to initiate pharmacotherapy for alcohol withdrawal is typically based on examining self‐reported use of alcohol and symptoms of withdrawal. Phosphatidylethanol (PEth) is a biomarker that could aim in clinical decision‐making in withdrawal management.
Methods
This report describes three cases highlighting the potential clinical utility of PEth in caring for individuals at risk for alcohol withdrawal.
Results
Two of the cases received phenobarbital when their PEth showed that the risk of withdrawal was low and one case where PEth could have shown this was needed. The results were only available in a delayed fashion, however, could have been useful in informing clinical care. Discussion and Conclusion PEth can be a useful tool if available without delay. PEth can be used to quickly rule out alcohol withdrawal and avoid misdiagnoses and prolonged hospital stays. Scientific Significance This is a clinical case study available looking at PEth and withdrawal in hospitalized patients. It proposes that PEth can be used as a way to quickly rule out alcohol withdrawal to avoid misdiagnoses and the possibility of a prolonged hospital stay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts, USA.
- Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Psychiatry, Massachusetts General Hospital, Boston, United States, USA.
ORCID-Profile: Amber N Edinoff, Joji Suzuki
Förderung
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Edinoff, A. N., Hathaway, D. B., Martinez Garza, D., Rosen, J. H., & Suzuki, J. (2024). The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report. The American Journal on Addictions. https://doi.org/10.1111/ajad.13516
Vancouver
Edinoff AN, Hathaway DB, Martinez Garza D, Rosen JH, Suzuki J. The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report. The American Journal on Addictions. 2024. doi:10.1111/ajad.13516
BibTeX
@article{Edinoff2024,
author = {Edinoff, Amber N and Hathaway, David B and Martinez Garza, David and Rosen, Jordan H and Suzuki, Joji},
title = {The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report},
journal = {The American Journal on Addictions},
year = {2024},
doi = {10.1111/ajad.13516}
}
EUVIMED